On May 20, 2026, Gloria Melanie, Chief Operating Officer at Immunovant, Inc. (NASDAQ:IMVT), conducted a sale of corporate stock. Specifically, she sold 3,115 shares of the company's common stock for a total proceeds valued at $101,072. The selling price averaged between $30.41 and $32.95 per share.
It is noted that Immunovant’s current trading price stands at $34.15. This level is situated close to the company's 52-week high of $36.28, following a significant appreciation of 134% over the last year. The biotech firm maintains a market capitalization of $6.95 billion. However, an analysis from InvestingPro suggests that the stock may be considered overvalued when compared to its calculated Fair Value, leading to its inclusion among companies flagged on the Most Overvalued list.
Context of the Stock Sale
The divestiture was not a discretionary action by Ms. Melanie. The sales were executed as part of a mandatory process required to satisfy tax withholding duties. These obligations arose from the vesting and settlement of 6,872 restricted stock units (RSUs) that became available on May 18, 2026. According to company policy, such transactions necessitate a